22 May 2023 – Yourgene Genomic Services to support MHC’s Boots agreement

Yourgene Health plc

(“Yourgene” or the “Group” or the “Company”)

Yourgene Genomic Services to support MHC’s Boots agreement

Manchester, UK – 22 May 2023: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces that its partner MyHealthChecked plc (AIM: MHC) (“MyHealthChecked”) has entered into an agreement via its subsidiary Concepta Diagnostics Limited with Boots UK Limited (“Boots”), the health and beauty retailer and pharmacy group, to launch its extended range of at-home self-testing products tests via boots.com and across 120 Boots stores in Great Britain and Northern Ireland.

Through the service agreement, five out of the 14 tests MyHealthChecked are launching via Boots, will be processed by Yourgene Genomic Services (“YGS”) at the Company’s accredited laboratory in Manchester. The DNA cheek swab tests, that look at a range of wellbeing factors such as glucose and weight management, heart profiling, intolerance and sensitivities and finally vitamin and minerals DNA testing, are already available online to purchase via boots.com.

Lyn Rees, Chief Executive Officer of Yourgene, commented: “We would like to congratulate our partner MyHealthChecked on their retail launch with Boots of their extended product portfolio, which demonstrates execution of the next step of their strategic plan. Yourgene is proud to continue to support MyHealthChecked with our state-of-the-art laboratory and the contract is a testament to the quality of the service we provide.”

Yourgene Health plc

Lyn Rees, Chief Executive Officer
Joanne Cross, Director of Marketing

Tel: +44 (0)161 669 8122


Walbrook PR Ltd (Media and Investor Relations)

Paul McManus / Alice Woodings / Lianne Applegarth

Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com

Mob: 07980 541 893 / Mob: 07407 804 654 / Mob: 07584 391 303

About Yourgene Health

Yourgene Health is an international integrated technologies and services business, enabling the delivery of genomic medicine. The Group works in partnership with global leaders in DNA technology to advance diagnostic science.

Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic and screening solutions, for reproductive health and precision medicine. The Group’s portfolio of in vitro diagnostic products includes non-invasive prenatal tests (NIPT) for Down’s Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests and DPYD genotyping assays.

Building on our expertise in genomic technology, Yourgene’s Ranger® Technology offers next generation size selection with a range of sample preparation platforms for dynamic target enrichment. Ranger® Technology can be utilised to improve workflows and performance in multiple applications including NIPT, oncology, infectious disease testing and gene synthesis.

Yourgene Genomic Services offers a clinical service from UK and Taiwan focusing on precision medicine and reproductive health, including NIPT.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange’s AIM market under the ticker “YGEN”.

For more information visit https://yourgenehealth.com/ and follow us on twitter @Yourgene_Health.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.